General Announcement::GPL Announces Decision to Launch Phase 1 Trial in Solid Tumors

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
08-Nov-2018 13:52:41
Status
New
Announcement Sub Title
GPL Announces Decision to Launch Phase 1 Trial in Solid Tumors
Announcement Reference
SG181108OTHREOFJ
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
08/11/2018 11:22:00
Description (Please provide a detailed description of the event in the box below)
Sub: Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Attachments

SGX_PR_0811.pdf
Total size =221K